These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Somatic POLE mutations cause an ultramutated giant cell high-grade glioma subtype with better prognosis. Erson-Omay EZ; Çağlayan AO; Schultz N; Weinhold N; Omay SB; Özduman K; Köksal Y; Li J; Serin Harmancı A; Clark V; Carrión-Grant G; Baranoski J; Çağlar C; Barak T; Coşkun S; Baran B; Köse D; Sun J; Bakırcıoğlu M; Moliterno Günel J; Pamir MN; Mishra-Gorur K; Bilguvar K; Yasuno K; Vortmeyer A; Huttner AJ; Sander C; Günel M Neuro Oncol; 2015 Oct; 17(10):1356-64. PubMed ID: 25740784 [TBL] [Abstract][Full Text] [Related]
4. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. Tachibana I; Smith JS; Sato K; Hosek SM; Kimmel DW; Jenkins RB Am J Med Genet; 2000 May; 92(2):136-41. PubMed ID: 10797439 [TBL] [Abstract][Full Text] [Related]
5. Germline ALK variations are associated with a poor prognosis in glioma and IDH-wildtype glioblastoma. Bu L; Hameed NUF; Luo C; Hong P; Zhou X; Wang S; Wu S J Neurooncol; 2021 Mar; 152(1):27-36. PubMed ID: 33486679 [TBL] [Abstract][Full Text] [Related]
6. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047 [TBL] [Abstract][Full Text] [Related]
7. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743 [TBL] [Abstract][Full Text] [Related]
8. Genetic risk variants in the CDKN2A/B, RTEL1 and EGFR genes are associated with somatic biomarkers in glioma. Ghasimi S; Wibom C; Dahlin AM; Brännström T; Golovleva I; Andersson U; Melin B J Neurooncol; 2016 May; 127(3):483-92. PubMed ID: 26839018 [TBL] [Abstract][Full Text] [Related]
9. Dissecting Molecular Features of Gliomas: Genetic Loci and Validated Biomarkers. Arcella A; Limanaqi F; Ferese R; Biagioni F; Oliva MA; Storto M; Fanelli M; Gambardella S; Fornai F Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31968687 [TBL] [Abstract][Full Text] [Related]
10. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203 [TBL] [Abstract][Full Text] [Related]
11. Tumor genomic profiling and TP53 germline mutation analysis of first-degree relative familial gliomas. Idbaih A; Boisselier B; Sanson M; Crinière E; Liva S; Marie Y; Carpentier C; Paris S; Laigle-Donadey F; Mokhtari K; Kujas M; Hoang-Xuan K; Delattre O; Delattre JY Cancer Genet Cytogenet; 2007 Jul; 176(2):121-6. PubMed ID: 17656254 [TBL] [Abstract][Full Text] [Related]
13. Characterization of gliomas: from morphology to molecules. Ferris SP; Hofmann JW; Solomon DA; Perry A Virchows Arch; 2017 Aug; 471(2):257-269. PubMed ID: 28674742 [TBL] [Abstract][Full Text] [Related]
14. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Cimino PJ; Zager M; McFerrin L; Wirsching HG; Bolouri H; Hentschel B; von Deimling A; Jones D; Reifenberger G; Weller M; Holland EC Acta Neuropathol Commun; 2017 May; 5(1):39. PubMed ID: 28532485 [TBL] [Abstract][Full Text] [Related]
15. A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal. Sun JX; He Y; Sanford E; Montesion M; Frampton GM; Vignot S; Soria JC; Ross JS; Miller VA; Stephens PJ; Lipson D; Yelensky R PLoS Comput Biol; 2018 Feb; 14(2):e1005965. PubMed ID: 29415044 [TBL] [Abstract][Full Text] [Related]
16. A Comparative Study of the Molecular Characteristics of Familial Gliomas and Other Cancers. Lu J; Burnett MG; Shpak M Cancer Genomics Proteomics; 2016 11-12; 13(6):467-474. PubMed ID: 27807069 [TBL] [Abstract][Full Text] [Related]
17. Molecular Diagnostic and Prognostic Subtyping of Gliomas in Tunisian Population. Trabelsi S; Chabchoub I; Ksira I; Karmeni N; Mama N; Kanoun S; Burford A; Jury A; Mackay A; Popov S; Bouaouina N; Ben Ahmed S; Mokni M; Tlili K; Krifa H; Yacoubi MT; Jones C; Saad A; H'mida Ben Brahim D Mol Neurobiol; 2017 May; 54(4):2381-2394. PubMed ID: 26957305 [TBL] [Abstract][Full Text] [Related]
18. Sequential filtering for clinically relevant variants as a method for clinical interpretation of whole exome sequencing findings in glioma. Ülgen E; Can Ö; Bilguvar K; Akyerli Boylu C; Kılıçturgay Yüksel Ş; Erşen Danyeli A; Sezerman OU; Yakıcıer MC; Pamir MN; Özduman K BMC Med Genomics; 2021 Feb; 14(1):54. PubMed ID: 33622343 [TBL] [Abstract][Full Text] [Related]